Vinge has represented Inflexion in connection with the acquisition of the Mecenat group from IK. The acquisition of Mecenat is the first investment made through Inflexion's new Enterprise Fund VI, and Inflexion's first acquisition in Sweden.

Mecenat is a digital marketplace that connects students, alumni, young professionals, and seniors with well-known brands by offering access to exclusive deals, career services, and relevant events. The Mecenat group operates in both Sweden and Finland, has approximately three million members, and collaborates with more than 700 local and global brands. Mecenat's platform spans various industries, including technology, fashion, travel and entertainment.

Vinge's team mainly consisted of Christina Kokko, Maria Dahlin Kolvik, Eléonore Friberg, Carl Fredrik Wachtmeister, Madelene Andersson, and Chris Bastholm (M&A), Victor Ericsson (Tax), Helena Göransson, Karl-Gustaw Tobola, August Ahlin, and Matilda Hamner (Banking and Finance), Ian Jonsson and Siri Blomberg (IP), Simon Söderholm and Linn Aho (Employment), Carla Håkansson and Hanna Kövamees (Commercial Agreements), Katja Häglund (GDPR), Hayaat Ibrahim (Compliance), Nils Unckel and Anton Sjökvist (AIFMD), Lovisa Lewin and Alva Chambert (Competition Law and FDI), and Caroline Löv (Transaction Support Coordinator).

For more information, please see the client's press release here

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026